Edesa Biotech, Inc. (EDSA)
NASDAQ: EDSA · Real-Time Price · USD
2.670
+0.020 (0.75%)
At close: Oct 15, 2026, 4:00 PM EDT
2.650
-0.020 (-0.75%)
After-hours: Oct 15, 2026, 7:30 PM EDT
Edesa Biotech Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
17
Market Cap
36.08M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2025 | - | - | - |
| Sep 30, 2024 | - | - | - |
| Sep 30, 2023 | - | - | - |
| Sep 30, 2022 | - | - | - |
| Sep 30, 2021 | - | - | - |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
EDSA News
- 17 hours ago - Edesa Biotech announces FDA clearance for vitiligo study - TheFly
- 17 hours ago - Edesa Biotech Announces FDA IND Clearance for Phase 2 Vitiligo Study - GlobeNewsWire
- 1 month ago - Edesa Biotech 3.87M share Spot Secondary priced at $5.50 - TheFly
- 1 month ago - Edesa Biotech Announces Pricing of $25.0 Million Public Offering - GlobeNewsWire
- 1 month ago - Edesa Biotech announces offering of common stock and warrants, no amount given - TheFly
- 1 month ago - Edesa Biotech Announces Proposed Public Offering - GlobeNewsWire
- 2 months ago - Edesa Biotech Reports Fiscal 3rd Quarter 2026 Results - GlobeNewsWire
- 3 months ago - Edesa Biotech files to sell 729,241 common shares for holders - TheFly